4.7 Review

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

Journal

CANCER LETTERS
Volume 269, Issue 1, Pages 7-17

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.03.037

Keywords

historic deacetylase inhibitor; apoptosis; autophagy; bortezomib; TRAIL

Categories

Funding

  1. Institute for Drug Development, Cancer Therapy and Research Center at The Umversity of Texas Health Science Center at San Antonio

Ask authors/readers for more resources

Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation and promoting transcriptional repression. Since aberrant epigenetic changes are a hallmark of cancer, HDACs are a promising target for pharmacological inhibition. HDAC inhibitors can induce cell-cycle arrest, promote differentiation, and stimulate tumor cell death. These properties have prompted numerous preclinical and clinical investigations evaluating the potential efficacy of HDAC inhibitors for a variety of malignancies. The preferential toxicity of HDAC inhibitors in transformed cells and their ability to synergistically enhance the anticancer activity of many chemotherapeutic agents has further generated interest in this novel class of drugs. Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available